 The Report provides newly researched company profiles and competitive intelligence on over 50 leading OTC producers (see full list below) operating in 14 key markets: Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.
There is great potential in the Asian market for regionally-based OTC manufacturers with strong marketing divisions, but growth rates and trends will be far from uniform across the region. We evaluate and forecast the impact in each state of the key OTC demand drivers; ageing populations, a lower reliance on traditional remedies, the switching of prescription drugs to OTC and increased patient responsibility for healthcare.
Asia Pacific's Leading OTC Medicine Markets features BMI's independent 5-year industry forecasts for each market to end-2012. Crucially, our long term views are founded upon our unique Business Environment Rating – a numerically-based risk-reward evaluation of the competitiveness of the regulatory and business operating environment for each of the 14 OTC markets; a vital tool for benchmarking both the rewards available in each state and the risks of market entry.
Rapid market expansion WILL occur. BMI forecasts that the Asian OTC market will expand at a compound annual growth rate (CAGR) of 7.02% over 2008-2012, with a total market value of US$52bn by 2012 – up from US$36bn in 2007. Moreover, while economic development is a key driver, it is the trends that this propels – a move away from traditional drugs, and government moves to contain healthcare costs – that will determine the rate of OTC market expansion.
'Chindia' will be the key market. Japan is currently the largest OTC market at US$11.02bn in 2007, but growth here will stagnate. The value of its market will be rapidly eclipsed by China and India, which between them will account for 47% of the Asian OTC market by 2012, with analgesics to remain the hottest products.
Furthermore, there are risks. The potential is there, but our forecasts are based on assumptions regarding market access and government health policies that are vulnerable to change. How companies manage these risks will depend on the opportunities available, their ability to build strategic relationships with key stakeholders, and the regional diversification strategies of their clients and competitors.
Key Benefits of the Report
Identify and evaluate the scale of growth opportunities across 14 key markets for OTC producers – including small, growing and little understood markets
Benchmark competitors and peers in each market using recently researched company profiles, featuring latest intelligence on over 50 OTC companies, analysing competitive positioning, opportunities, risks and strategies of each company
Benchmark your own views and forecasts for market performance against BMI's independent 5-year industry forecasts for OTC drugs
Use BMI's country-comparative business environment ratings to assess the operating risks, opportunities and key factors impacting corporate profitability in each of the 14 markets covered
Executives who will benefit most from this Report:
Strategists – Gain an insight into the commercial opportunities available in Asia's OTC market, using our clearly-explained medium-term economic forecasts (2008-2012) to benchmark your own growth projections.
Risk Managers – Discover the key Industry, Political, Economic and Operational risks facing companies in these rapidly developing states, and exploit BMI's quantitatively-based risk assessment model to stress-test your own assumptions.
Country Managers - Gain an insight into the country-specific growth trajectories and the key strengths of your clients and competitors.
Financial Planners – Critically evaluate the assumptions underpinning your medium-term financial projections using BMI's growth projections for the future direction and value of the currency and key domestic interest rates; the principal determinant of business investment and consumer spending growth.
List of over 50 leading OTC companies profiled in Asia Pacific's Leading OTC Medicine Markets:
Australia (Novartis, Roche, Sigma Pharmaceuticals, Herron Pharmaceuticals)
China (GlaxoSmithKline, Merck & Co, Bayer, Hubei Biocause Heilen Pharmaceutical, Shijiazhuang Pharmaceutical)
Hong Kong (Visa Laboratories, GlaxoSmithKline)
India (Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis)
Indonesia (Novartis, GlaxoSmithKline, Bayer, PT Kalbe Farma)
Japan Novartis, GlaxoSmithKline, Eisai)
Malaysia (GlaxoSmithKline, Novartis, Bumimedic, Chemical Company of Malaysia, Kotra Pharma, YSP Southeast Holding)
Pakistan (Novartis, Wyeth)
Philippines (GlaxoSmithKline, Pfizer, Novartis, Bristol-Myers Squibb, Wyeth, Unilab, Pascual Laboratories)
Singapore (GlaxoSmithKline, Haw Par Corporation Ltd)
South Korea (Dong-A, Yuhan Corporation, Daewoong Pharmaceutical, Bukwang Pharmaceutical Company)
Taiwan (GlaxoSmithKline, Novartis)
Thailand (Pfizer, GlaxoSmithKline, Novartis, Government Pharmaceuticals Organisation)
Vietnam (Vietnam OPV Pharmaceutical Co)
|
